Details of the Drug

General Information of Drug (ID: DMP6SC2)

• Drug Name: Irinotecan
• Synonyms: Biotecan; Camptosar; Irinotecanum; IRINOTECAN HYDROCHLORIDE Trihydrate; Irinotecan Hcl; Irinotecan hydrochloride; CP0; Biotecan (TN); Campto (TN); Camptosar (TN); Irinotecan (INN); Irinotecan [INN:BAN]; Irinotecanum [INN-Latin]; IRINOTECAN, CPT-11; Camptosar, Campto, CPT-11, Irinotecan; (+)-Irinotecan; (4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE; (4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate; Irinotecan (TOPO1 inhibitor); Onivyde

Indication

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[1]
Advanced cancer	2A00-2F9Z	Approved	[1]
Appendiceal neoplasm	N.A.	Approved	[1]
Astrocytoma	2A00.0Y	Approved	[1]
Brain glioma	N.A.	Approved	[1]
Colon adenocarcinoma	N.A.	Approved	[1]
Colorectal cancer	2B91.Z	Approved	[2]
Endocrine gland neoplasm	N.A.	Approved	[1]
Kidney neoplasm	N.A.	Approved	[1]
Metastasis from malignant tumor of colon	N.A.	Approved	[1]
Peritoneal neoplasm	N.A.	Approved	[1]
Rectal adenocarcinoma	2B92	Approved	[1]
Rectal neoplasm	N.A.	Approved	[1]
Rectum mucinous adenocarcinoma	N.A.	Approved	[1]
Adult glioblastoma	N.A.	Investigative	[1]
Colon cancer	2B90.Z	Investigative	[1]
Colon mucinous adenocarcinoma	N.A.	Investigative	[1]
Diarrhea	ME05.1	Investigative	[1]
Gastric cancer	2B72	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01CE02: Irinotecan
  L01CE: Topoisomerase 1 (TOP1) inhibitors
  L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 586.7
  Logarithm of the Partition Coefficient (xlogp); 3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 10,200 mcgh/L []
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 1660 mcg/L []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 7 mL/min/kg [4]
  Elimination: 16.7% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 12 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7548 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.51% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.5 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Drug toxicity	rs2745761	PLCB1	OT9HYT7A	[6]
Drug toxicity	rs1517114	C8orf34	OTXCTHDG	[6]
Neutropenia	rs17318866	FAM50B	OTP3H38A	[7]
Neutropenias	rs4149056	SLCO1B1	OTNEN8QK	[8]

• Chemical Identifiers:
  Formula: C33H38N4O6
  IUPAC Name: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
  Canonical SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
  InChI: InChI=1S/C33H38N4O6/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3/t33-/m0/s1
  InChIKey: UWKQSNNFCGGAFS-XIFFEERXSA-N
• Cross-matching ID:
  PubChem CID: 60838
  ChEBI ID: CHEBI:80630
  CAS Number: 97682-44-5
  UNII: 7673326042
  DrugBank ID: DB00762
  TTD ID: D07HOB
  VARIDT ID: DR00112
  INTEDE ID: DR0881
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Modulator	[9]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 5 (ABCC5)	DTYVM24	MRP5_HUMAN	Substrate	[10]
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[11]
Multidrug resistance-associated protein 4 (ABCC4)	DTCSGPB	MRP4_HUMAN	Substrate	[12]
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[13]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[14]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[16]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[17]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[18]
Carboxylesterase 1 (CES1) Main DME	DEB30C5	EST1_HUMAN	Substrate	[15]
Carboxylesterase 2 (CES2) Main DME	DETHCPD	EST2_HUMAN	Substrate	[19]
Carboxylesterase 3 (CES3) Main DME	DEMI4VE	EST3_HUMAN	Substrate	[19]
Beta-glucuronidase (uidA)	DE9RA0I	BGLR_ECOLI	Substrate	[20]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1)	OT9HYT7A	PLCB1_HUMAN	Drug Response	[6]
2-(3-amino-3-carboxypropyl)histidine synthase subunit 2 (DPH2)	OT9P91XR	DPH2_HUMAN	Gene/Protein Processing	[21]
3',5'-cyclic-AMP phosphodiesterase 4B (PDE4B)	OTOA8WU2	PDE4B_HUMAN	Gene/Protein Processing	[22]
3-mercaptopyruvate sulfurtransferase (MPST)	OTCDPH5D	THTM_HUMAN	Gene/Protein Processing	[23]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	OT7TNF0L	AAPK1_HUMAN	Gene/Protein Processing	[21]
5-aminolevulinate synthase, erythroid-specific, mitochondrial (ALAS2)	OTJXOUCL	HEM0_HUMAN	Gene/Protein Processing	[22]
5-formyltetrahydrofolate cyclo-ligase (MTHFS)	OTZ39JNR	MTHFS_HUMAN	Gene/Protein Processing	[22]
A-kinase anchor protein 10, mitochondrial (AKAP10)	OTPNFTOU	AKA10_HUMAN	Gene/Protein Processing	[22]
Abl interactor 2 (ABI2)	OT8GIIS5	ABI2_HUMAN	Gene/Protein Processing	[23]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Drug Response	[24]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC2	2.1324	4.6641	1.5127	15.454
EW-13	GDSC2	-7.5371	34.0518	-21.8211	57.006
EW-3	GDSC2	-6.9299	3.8273	-8.0082	70.8682
ES7	GDSC2	-3.7524	1.1785	-3.9365	62.0451
CADO-ES1	GDSC2	-2.1186	2.4851	-2.4097	49.6692
EW-22	GDSC2	-1.9527	0.2398	-1.9627	48.1194
EW-12	GDSC2	-1.7764	-0.3796	-1.7784	41.1364
ES1	GDSC2	-1.1496	1.0535	-1.1725	44.9459
ES8	GDSC2	-1.1287	0.862	-1.142	40.644
SW1353	CCLE	-0.7655	1.7154	-0.8432	32.6696
SK-ES-1	GDSC2; CCLE	-0.6423	0.9972	-0.6496	33.1598
EW-11	GDSC2	-0.6205	4.3981	-1.316	38.4256
EW-1	GDSC2	-0.5328	3.098	-0.8258	36.3475
SK-PN-DW	GDSC2	-0.466	1.8763	-0.5254	34.8086
A-673	GDSC2	-0.4473	2.6575	-0.6311	35.1614
EW-16	GDSC2	-0.2029	3.2719	-0.5113	33.4906
TC-71	GDSC2; CCLE	-0.0658	2.1643	-0.1354	28.6059
MHH-ES-1	GDSC2; CCLE	-0.0103	2.3587	-0.1041	28.2453
EW-7	GDSC2	0.3472	4.0727	-0.1566	29.4582
EW-24	GDSC2	0.3476	6.3342	-1.0519	33.0286
HuO9	GDSC2	0.5231	2.7571	0.4011	26.0954
ES5	GDSC2	0.7357	8.8629	-2.3491	30.8683
ES4	GDSC2	0.7906	5.967	-0.4358	28.8068
SaOS-2	GDSC2; CCLE	1.2753	3.8701	0.9178	18.7084
SJSA-1	GDSC2	1.6282	5.0857	0.8102	21.5463
NY	GDSC2	2.0255	4.3475	1.5378	14.3005
HOS	GDSC2; CCLE	2.1788	2.8924	2.1601	9.6323
MG-63	GDSC2; CCLE	2.2618	5.5582	1.232	13.8782
H-EMC-SS	GDSC2	2.3678	6.7008	0.7837	17.2261
CHSA0011	GDSC2	2.8169	6.6531	0.5538	9.7922
CAL-72	GDSC2	2.8533	5.5644	1.7896	10.1366
ES6	GDSC2	3.3686	5.2296	2.4067	5.1443
CAL-78	GDSC2; CCLE	3.4374	8.1078	1.0245	11.7768
HuO-3N1	GDSC2	3.5106	5.372	2.4496	4.5429
U-CH2	GDSC2	3.5732	6.9333	0.9571	5.5989
CHSA8926	GDSC2	4.6089	7.2958	2.2775	3.3391
CHSA0108	GDSC2	4.6225	13.6278	-1.5474	16.5513
G-292 clone A141B1	GDSC2	4.8696	7.6607	2.2663	3.0006
EW-18	GDSC2	5.9232	11.0515	1.3496	5.9761
U2OS	GDSC2; CCLE	5.9548	7.913	2.6812	0.3784
NOS-1 [Human HNSCC]	GDSC2	6.2114	8.4732	2.5778	0.5504

Cancer Drug Sensitivity Data Curated from 181 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JM1	GDSC2	-0.116	0.6631	-0.1167	24.4687
KE-97	CCLE	-5.218	-3.0364	-5.2185	70.314
Kasumi-2	CCLE	-4.5142	-2.9897	-4.5143	64.5186
KMS-34	CCLE	-4.4738	-3.3059	-4.4738	64.1851
BL-70	CCLE	-4.4201	-2.8601	-4.4202	63.71
Ci-1	CCLE	-4.1414	-0.5459	-4.1825	60.6398
Mino	CCLE	-4.0193	-1.1142	-4.0323	60.0009
KHM-1B	CCLE	-3.7309	-2.1976	-3.731	57.802
KMS-26	CCLE	-3.5978	-1.7579	-3.5984	56.6485
MEC-1	CCLE	-3.581	-0.6372	-3.6006	56.3433
MOLT-4	GDSC2	-3.3497	1.0763	-3.4914	59.4421
Mono-Mac-1	CCLE	-3.2906	-1.2231	-3.2929	54.0077
KO52	CCLE	-3.22	-1.9395	-3.2201	53.4187
CMK-86	CCLE	-3.1418	-1.6042	-3.142	52.7459
NCO2	CCLE	-2.7984	-0.93	-2.8003	49.7984
JVM-3	GDSC2; CCLE	-2.3504	1.5831	-2.495	47.5826
KMM-1	CCLE	-2.2825	0.0867	-2.2984	45.4104
U-937	CCLE	-2.2603	-1.2392	-2.2604	45.177
DoHH2	GDSC2; CCLE	-2.2422	1.2771	-2.3592	45.2821
OCI-Ly19	GDSC2	-2.0565	-0.726	-2.0573	43.9413
MV4-11	GDSC2	-1.6346	0.6653	-1.6529	45.2563
Namalwa	GDSC2	-1.5151	2.6877	-1.7982	44.7575
CML-T1	GDSC2	-1.4637	-0.2472	-1.4638	43.6449
MOLM-13	GDSC2	-1.4599	1.1526	-1.5018	43.7431
ALL-PO	GDSC2	-1.2745	4.2338	-1.9699	43.5746
BONNA-12	GDSC2	-1.2304	1.2034	-1.3167	36.0553
MOLT-16	GDSC2; CCLE	-1.126	0.4189	-1.1285	37.1827
WIL2 NS	GDSC2	-1.0789	1.1038	-1.1023	40.2302
MHH-CALL-4	GDSC2	-1.0575	1.3115	-1.1476	34.3503
697	GDSC2; CCLE	-0.8962	0.7253	-0.901	35.2717
F-36P	CCLE	-0.8798	0.547	-0.8831	33.3343
SU-DHL-16	GDSC2	-0.8778	1.687	-1.0194	32.8057
P12-Ichikawa	GDSC2; CCLE	-0.8694	0.0359	-0.8695	35.0279
SU-DHL-5	GDSC2	-0.8461	0.1441	-0.8462	38.0127
DEL	GDSC2; CCLE	-0.8445	0.4371	-0.8455	34.8238
RPMI-8402	GDSC2; CCLE	-0.8252	0.6388	-0.8279	34.6695
NU-DUL-1	GDSC2	-0.82	1.9006	-1.0017	32.4245
SIG-M5	GDSC2; CCLE	-0.801	-0.3707	-0.801	32.6442
SUP-B8	GDSC2	-0.7133	0.9661	-0.7415	30.6008
SU-DHL-1	GDSC2	-0.7001	1.8231	-0.8545	31.0995
RPMI-6666	GDSC2	-0.6899	2.6727	-0.8977	37.4197
SUP-M2	GDSC2; CCLE	-0.6352	0.1082	-0.6352	33.0707
P32/ISH	GDSC2	-0.5947	0.4765	-0.595	35.7207
SUP-B15	GDSC2	-0.5612	1.0703	-0.5691	35.4491
NB4	GDSC2	-0.5194	0.4949	-0.5214	28.5231
A3/Kawakami	GDSC2	-0.5188	0.5445	-0.5192	35.0288
VL51	GDSC2	-0.5094	1.8489	-0.5683	35.201
SR	GDSC2	-0.4595	1.1663	-0.4684	34.5266
CRO-AP2	GDSC2	-0.4061	2.8429	-0.8123	29.4431
EB2	GDSC2	-0.4047	2.1569	-0.4964	34.3916
BV-173	GDSC2	-0.352	0.613	-0.3522	33.5066
BALL-1	GDSC2	-0.3388	0.888	-0.3404	33.3928
IM-9	GDSC2	-0.3148	1.4675	-0.3329	33.249
LC4-1	GDSC2	-0.249	2.1114	-0.3238	32.9035
MHH-CALL-2	GDSC2	-0.2294	1.021	-0.2316	32.398
SU-DHL-8	GDSC2; CCLE	-0.2239	0.7465	-0.2242	29.6346
SUP-T1	GDSC2	-0.2179	2.8793	-0.4299	33.2201
KOPN-8	GDSC2	-0.1958	2.2422	-0.2853	32.4853
SCC-3	GDSC2	-0.1892	0.5824	-0.1892	32.021
YT	GDSC2	-0.0933	4.39	-0.7432	36.9816
H9	GDSC2	-0.0835	1.5321	-0.0976	31.1216
JSC-1	GDSC2	-0.0518	1.5738	-0.0671	30.8381
MC116	GDSC2	-0.0368	3.1983	-0.5353	26.2979
DND-41	GDSC2	-0.0329	1.7452	-0.0581	30.7108
Karpas-231	GDSC2	-0.0325	0.9664	-0.033	30.5944
CESS	GDSC2	-0.0221	1.7034	-0.044	30.5972
PF-382	GDSC2	-0.0094	1.902	-0.0464	30.5504
ALL-SIL	GDSC2; CCLE	0.0329	2.1445	-0.0279	27.744
CTB-1	GDSC2	0.0411	2.2841	-0.157	23.9246
BL-41	GDSC2; CCLE	0.0413	0.8817	0.0411	27.4176
Granta-519	GDSC2; CCLE	0.0421	3.3349	-0.261	28.7023
CCRF-CEM	GDSC2	0.0581	1.306	0.0545	29.7821
SU-DHL-6	GDSC2; CCLE	0.0658	2.3703	-0.0243	27.5942
WSU-DLCL2	GDSC2	0.0769	2.2123	0.0103	32.894
SUP-HD1	GDSC2	0.0873	2.8986	-0.1022	30.3676
HC-1	GDSC2	0.0908	1.6533	0.0758	29.5361
RCH-ACV	GDSC2	0.0916	1.4431	0.0596	22.5443
TALL-1 [Human adult T-ALL]	GDSC2	0.0934	3.0633	-0.3465	24.7054
JVM-2	GDSC2	0.1376	2.3359	0.0578	29.4081
KE-37	GDSC2	0.1439	1.5158	0.1363	29.0181
Jurkat	GDSC2; CCLE	0.1713	1.6688	0.158	26.3862
Mono-Mac-6	GDSC2	0.183	2.5756	0.0675	32.0737
VAL	GDSC2	0.1902	2.2366	0.1278	28.8488
L-540	GDSC2	0.2348	2.5226	0.1326	28.627
MY-M12	GDSC2	0.2441	1.3062	0.2312	20.9166
SKM-1	GDSC2	0.2686	1.9938	0.1614	21.1612
NALM-6	GDSC2	0.27	1.0803	0.2699	27.8337
CTV-1	GDSC2	0.2711	1.7637	0.2561	27.892
ML-2	GDSC2	0.279	1.5497	0.273	27.7787
OCI-Ly7	GDSC2	0.2826	1.8293	0.2089	20.8442
WSU-NHL	GDSC2	0.2847	2.1105	0.2428	27.8926
Raji	GDSC2	0.2929	2.0871	0.2538	27.8044
Hs 445	GDSC2	0.3197	2.0106	0.2892	27.5201
MOLT-13	GDSC2	0.3375	1.6953	0.3277	27.2624
ARH-77	GDSC2	0.3485	1.515	0.3446	27.1355
Farage	GDSC2	0.3784	3.6509	-0.267	23.0215
Reh	GDSC2	0.4224	1.6478	0.4163	26.4714
LP-1	GDSC2; CCLE	0.432	3.1741	0.1481	23.3355
OCI-AML-2	GDSC2; CCLE	0.4389	2.0167	0.4135	24.201
RS4;11	GDSC2	0.4768	1.8423	0.4642	26.005
NK-92MI	GDSC2	0.5066	1.8641	0.4444	18.5366
RL	GDSC2	0.5101	3.4101	-0.031	21.1458
A4/Fukuda	GDSC2	0.5123	2.8311	0.3744	26.2689
SU-DHL-4	GDSC2; CCLE	0.5303	3.7215	0.0782	23.2796
DB	GDSC2	0.5722	2.6821	0.4685	25.5613
PL-21	GDSC2	0.5754	2.7634	0.2794	19.1191
P31/FUJ	GDSC2; CCLE	0.5841	3.3194	0.3348	23.9679
NKM-1	GDSC2	0.5974	2.3727	0.5438	27.6132
ATN-1	GDSC2	0.6277	1.6301	0.6252	24.5824
KY821	GDSC2	0.6364	1.5467	0.6351	24.4975
EM-2	GDSC2; CCLE	0.6461	1.6534	0.6434	22.3736
Karpas-1106P	GDSC2	0.6473	4.1772	0.1317	26.8473
NOMO-1	GDSC2	0.656	2.0986	0.6337	24.4156
JeKo-1	GDSC2	0.6923	2.5874	0.4644	17.5717
QIMR-WIL	GDSC2	0.7123	2.9471	0.3622	18.0574
GDM-1	GDSC2	0.7659	3.5559	0.4652	24.7475
EoL-1	GDSC2	0.8233	2.1969	0.8007	22.8914
AMO1	GDSC2; CCLE	0.8578	3.4537	0.5956	21.7464
HL-60	GDSC2	0.8764	2.1818	0.8573	22.3905
MOLM-16	GDSC2	0.8858	3.0545	0.5077	16.4875
BC-1	GDSC2	0.9018	4.0522	0.4506	24.2562
OCI-AML-5	GDSC2; CCLE	0.9137	4.0422	0.3729	20.4445
BC-3	GDSC2	0.9235	2.8503	0.6247	15.6589
RPMI-8866	GDSC2	0.9459	3.8838	0.2249	17.8867
U-698-M	GDSC2	0.9467	5.331	-0.0013	26.2494
Jiyoye	GDSC2	1.0047	3.2666	0.8079	22.0712
OCI-M1	GDSC2	1.0173	2.2172	1.0014	21.0909
P30/OHK	GDSC2	1.0181	2.3346	0.993	21.1266
SK-MM-2	GDSC2; CCLE	1.0402	4.6494	0.3757	22.087
SU-DHL-10	GDSC2; CCLE	1.0877	4.1941	0.6001	20.8718
JURL-MK1	GDSC2	1.1634	3.0231	0.8153	13.5509
LAMA-84	GDSC2	1.1991	3.0421	1.0752	19.9459
HAL-01	GDSC2	1.2597	2.7264	1.2015	19.0783
Daudi	GDSC2	1.3714	4.4614	0.8015	20.6274
ROS-50	GDSC2	1.4049	3.9502	0.6575	13.5425
MLMA	GDSC2	1.515	5.8648	0.3482	22.3962
MEG-01	GDSC2; CCLE	1.5849	5.1187	0.7513	18.4234
GR-ST	GDSC2	1.5938	5.0123	0.8066	19.7621
MN-60	GDSC2	1.6275	5.6539	0.5571	20.9308
NCI-H929	GDSC2	1.6852	5.3646	0.7456	19.7463
HEL	GDSC2	1.7042	2.5483	1.5748	6.9025
Karpas-299	GDSC2	1.7122	3.6266	1.4734	17.4329
ST486	GDSC2	1.7192	5.3145	0.8026	19.3254
OCI-AML-3	GDSC2	1.7226	3.7959	1.4275	16.0359
Ku812	GDSC2; CCLE	1.7599	3.2374	1.6396	13.5794
MM1.S	GDSC2	1.7975	2.8306	1.7621	14.0672
THP-1	GDSC2	1.8014	2.7856	1.5837	6.4474
GA-10	GDSC2	1.8115	5.4203	0.8486	18.7531
KG-1	GDSC2; CCLE	1.8979	4.6106	1.2938	14.7288
BE-13	GDSC2	1.9296	5.1164	1.1049	16.9682
MOLP-8	GDSC2; CCLE	1.965	6.0724	0.6996	17.4527
TK [Human B-cell lymphoma]	GDSC2	2.0512	4.1394	1.65	13.61
RPMI-8226	GDSC2	2.164	5.3012	1.256	15.3348
HDLM-2	GDSC2	2.2949	5.8899	1.1064	15.7146
Karpas-422	GDSC2; CCLE	2.3016	7.5215	0.3211	18.2826
TUR	GDSC2	2.3434	4.8376	1.6483	12.5699
L-1236	GDSC2	2.3755	5.6869	1.281	14.4915
Kasumi-1	GDSC2	2.4965	5.3014	0.9751	8.0289
KM-H2	GDSC2	2.5067	5.176	1.6511	12.0069
OPM-2	GDSC2; CCLE	2.5271	5.5432	1.4951	11.7437
KMS-12-BM	GDSC2	2.5314	5.309	1.6115	12.1473
HT	GDSC2	2.5396	8.5771	-0.6261	17.3727
RC-K8	GDSC2	2.5431	4.9445	1.7962	11.0789
L-363	GDSC2; CCLE	2.5461	9.7608	-0.5649	21.5598
KMS-11	GDSC2; CCLE	2.5488	4.481	1.8566	7.4178
KCL-22	GDSC2; CCLE	2.5927	5.1741	1.735	10.3175
L-428	GDSC2; CCLE	2.8879	4.5165	2.3332	6.3689
KMOE-2	GDSC2	2.9	5.1496	2.0364	8.5926
MHH-PREB-1	GDSC2	3.0678	5.8553	1.8377	9.2338
Loucy	GDSC2	3.2921	8.9794	0.4683	16.1562
K-562	GDSC2	3.297	5.7258	2.0991	7.1018
DG-75	GDSC2	3.3628	6.3529	1.8403	8.4141
JJN-3	GDSC2	3.8136	7.6745	1.5406	8.9983
EJM	GDSC2	3.8192	6.5768	2.0881	5.8879
CA46	GDSC2	3.9108	7.5171	1.6926	7.9164
ME1	GDSC2	4.0211	7.8503	1.6107	8.1264
U266B1	GDSC2	4.3651	6.9867	2.2689	3.7933
Ramos.2G6.4C10	GDSC2	4.6008	5.8286	2.9069	0.4923
Karpas-45	GDSC2	4.6252	9.4179	1.2799	8.6492
Karpas-620	GDSC2; CCLE	5.2349	6.7025	2.8402	0.3096
HH [Human lymphoma]	GDSC2	5.759	7.7045	2.6804	0.4992

Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYSE-220	GDSC2	1.5089	3.9985	1.1246	18.4314
HCE-4	GDSC2	1.6317	4.107	0.8045	11.8194
TE-12	GDSC2	3.2195	6.3207	1.0121	6.0119
OACM5.1 C	GDSC2	3.3522	6.8914	1.5623	10.0292
ESO-26	GDSC2	3.5838	6.1774	2.1061	6.3332
OACP4 C	GDSC2	3.7144	5.7439	2.4205	4.2376
FLO-1	GDSC2	4.1192	7.3456	1.9296	6.13
ESO-51	GDSC2	4.3237	7.3739	2.0578	5.0117
SK-GT-4	GDSC2	4.5945	6.8863	2.4554	2.4604
KYAE-1	GDSC2	5.3828	7.1446	2.736	0.5392
KYSE-50	GDSC2	5.4086	7.1627	2.7398	0.5147

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC2	3.7788	9.0785	0.815	13.07

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KP-N-SI9s	CCLE	-4.7792	-1.4085	-4.7984	65.8718
SK-N-MC-IXC	GDSC2	-2.6973	0.1345	-2.7488	50.3537
SK-N-BE(2)	CCLE	-2.6365	-1.3785	-2.6365	48.4073
MHH-NB-11	GDSC2	-1.1964	1.4093	-1.3126	35.8524
CHP-126	GDSC2	-1.1669	3.0547	-1.7081	37.2654
KP-N-RT-BM-1	GDSC2	-0.6125	3.9121	-1.4212	33.2321
NB69	GDSC2	-0.2464	2.6774	-0.4171	33.2995
SJNB-10	GDSC2	0.2224	2.89	0.0467	29.0803
SJNB-17	GDSC2	0.393	2.1317	0.2655	20.022
SJNB-14	GDSC2	0.4057	3.961	-0.0555	28.7464
IMR-5	GDSC2	0.4528	1.5484	0.4496	26.1807
SiMa	GDSC2; CCLE	0.4823	4.3237	-0.0986	26.2806
NH-12	GDSC2	0.5052	4.7314	-0.2259	29.0853
CHP-134	GDSC2	0.8613	2.9236	0.7339	23.0403
KP-N-YN	GDSC2	1.0744	7.6809	-0.9292	29.6583
Kelly	GDSC2	1.1402	3.0613	1.0067	20.5291
KP-N-YS	GDSC2	1.1779	4.4475	0.2017	17.1284
SJNB-13	GDSC2	1.4591	4.6207	0.8303	20.1433
SK-N-DZ	GDSC2	1.5842	8.6943	-0.9213	27.7742
CHP-212	GDSC2	1.6295	6.1296	0.3417	22.0148
SJNB-5	GDSC2	1.8291	6.8916	-0.3856	18.2554
NB1	GDSC2	2.0928	6.0665	0.827	19.631
SK-N-SH	GDSC2	2.336	8.541	-0.1487	23.8643
GOTO	GDSC2	2.5142	7.4061	0.573	17.8783
LA-N-6	GDSC2	2.9528	6.4729	0.7459	8.266
SK-N-BE(2)-M17	GDSC2	2.9943	6.1278	1.6374	10.5871
NB(TU)1	GDSC2	3.182	6.5474	1.5912	10.3227
SK-N-FI	GDSC2	3.29	8.5667	0.6729	16.4831
SJNB-7	GDSC2	3.5557	6.9949	1.6764	8.8574
TGW	GDSC2	3.7531	7.8828	1.3901	9.9876
SJNB-12	GDSC2	3.9447	9.1523	0.9081	13.294
SK-N-AS	GDSC2	4.0698	11.7306	-0.2765	17.7259
SJNB-6	GDSC2	4.3345	5.8147	1.8382	0.3325
GI-ME-N	GDSC2	4.882	11.7643	0.3198	13.044

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuCC-T1	GDSC2; CCLE	1.98	7.042	0.2521	19.5677

Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SK-BR-3	CCLE	-4.2118	-0.6492	-4.2493	61.2216
CAL-148	GDSC2	-0.9876	1.3496	-1.024	43.3785
HCC1569	GDSC2; CCLE	-0.06	3.6061	-0.5227	28.3208
HMC-1-8	CCLE	0.2762	5.7167	-0.9872	28.9305
DU4475	GDSC2	0.5806	3.231	0.3546	26.0673
UACC-812	GDSC2; CCLE	1.1334	3.8946	0.7558	19.9818
MDA-MB-175-VII	GDSC2	1.4403	5.1261	0.5988	23.4928
HCC1599	GDSC2	1.5413	3.8437	0.8418	11.9171
Hs 739.T	CCLE	1.6776	7.396	-0.3783	21.4656
HCC1806	GDSC2	1.6856	6.2855	0.325	21.8978
CAL-51	GDSC2	1.9102	5.476	0.9224	18.0132
MDA-MB-468	GDSC2; CCLE	2.0779	3.6614	1.8584	11.3833
BT-549	GDSC2; CCLE	2.9407	5.4954	1.9031	8.458
MDA-MB-453	GDSC2; CCLE	3.082	10.7908	-0.6143	20.3242
HCC38	GDSC2	3.1494	4.6669	2.5008	5.2015
AU565	GDSC2	3.2169	6.7443	1.5224	10.6185
YMB-1-E	GDSC2	3.2272	6.6945	0.8364	7.0607
HCC2157	GDSC2	3.2392	4.9592	2.4334	5.3356
CAL-120	GDSC2	3.4395	8.1114	1.0245	12.8068
BT-20	GDSC2; CCLE	3.5753	5.6963	2.3388	4.6021
MDA-MB-231	GDSC2	3.6189	6.3202	2.0625	6.4982
UACC-893	GDSC2	3.6889	6.5247	1.221	3.8537
HCC1143	GDSC2	3.8833	7.1573	1.8496	7.093
HCC1428	GDSC2	3.8881	6.4128	2.2192	4.996
HCC1395	GDSC2	3.9849	10.7884	0.1258	17.4012
MDA-MB-157	GDSC2; CCLE	4.0223	6.7684	2.1417	4.7177
T-47D	GDSC2	4.0355	6.3317	2.3622	3.8974
HCC1500	GDSC2	4.0634	5.8357	2.6161	2.4691
HCC1419	GDSC2	4.1256	6.288	2.4433	3.2848
HDQ-P1	GDSC2; CCLE	4.1657	9.4903	0.9096	10.7152
MRK-nu-1	GDSC2	4.1871	9.3513	0.9944	11.134
HCC70	GDSC2; CCLE	4.2937	6.7824	2.3191	3.3459
MDA-MB-415	GDSC2	4.402	6.1732	2.664	1.7101
MDA-MB-436	GDSC2	4.4917	7.2136	2.2431	3.7114
HCC1937	GDSC2	4.53	7.5423	2.1136	4.3319
MDA-MB-361	GDSC2	4.61	8.1428	1.8819	5.4295
OCUB-M	GDSC2	4.6402	6.6089	2.6035	1.6892
MCF-7	GDSC2; CCLE	4.656	6.7135	2.5665	1.6871
HCC2218	GDSC2	4.7069	6.7757	1.6326	0.7221
JIMT-1	GDSC2	4.8037	7.9372	2.1011	3.9377
Hs 578T	GDSC2	4.9068	11.3931	0.5188	12.012
BT-483	GDSC2	5.0223	11.1449	0.7209	11.7107
CAL-85-1	GDSC2; CCLE	5.0512	9.701	1.4328	6.4425
COLO 824	GDSC2	5.1552	7.5535	2.4681	1.7017
Evsa-T	GDSC2	5.2284	6.7244	2.8296	0.3665
ZR-75-30	GDSC2; CCLE	5.2715	7.2438	2.65	0.8095
EFM-19	GDSC2; CCLE	5.2964	8.6193	2.0815	3.0296
BT-474	GDSC2	5.4142	6.8331	2.8618	0.2262
HCC1187	GDSC2	5.6348	7.2488	2.7971	0.2815
EFM-192A	GDSC2	5.6822	7.356	2.7769	0.3066
HCC1954	GDSC2	5.8939	8.0022	2.6245	0.58
MFM-223	GDSC2	5.9259	7.7173	2.7403	0.2988
MDA-MB-330	GDSC2	6.0142	8.0453	1.6727	0.1693
CAMA-1	GDSC2; CCLE	6.1806	15.5015	-0.5816	13.5434

Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SF126	GDSC2; CCLE	-2.7824	-0.2408	-2.7979	49.6651
KNS-60	CCLE	-1.2246	2.3058	-1.4411	37.1073
KNS-81	CCLE	-1.1213	2.0101	-1.2712	35.9928
D283 Med	GDSC2	0.1401	3.4126	-0.1757	30.4614
MOG-G-UVW	GDSC2	0.185	2.6353	0.0586	32.1068
D-245MG	GDSC2	0.4303	4.3683	-0.5165	24.1559
Daoy	GDSC2; CCLE	0.6571	4.8464	-0.1087	25.6687
Hs 683	GDSC2; CCLE	0.7847	3.981	0.2581	21.4712
SF295	GDSC2; CCLE	0.884	2.8499	0.7299	18.8626
AM-38	GDSC2	0.8998	3.2059	0.7093	22.9946
D-566MG	GDSC2	0.9595	3.0206	0.5993	15.6509
8-MG-BA	GDSC2	0.9788	2.8652	0.8735	21.8634
SW1783	GDSC2	1.0714	3.7616	0.7331	24.3757
GB-1	GDSC2; CCLE	1.0902	6.4393	-0.3404	25.1246
YKG-1	GDSC2; CCLE	1.1606	3.9084	0.6878	18.0142
H4	GDSC2	1.2476	4.1314	0.795	21.1451
D-336MG	GDSC2	1.5055	7.6959	-1.0724	22.9104
SF539	GDSC2	1.532	4.424	0.9867	19.0549
A-172	GDSC2; CCLE	1.5896	4.4804	1.0249	17.0836
GMS-10	CCLE	1.6639	5.6819	0.4304	17.5925
U-87MG ATCC	GDSC2; CCLE	1.7144	5.5115	0.7093	18.2003
D-423MG	GDSC2	1.9089	3.6988	1.2649	7.9991
GI-1	GDSC2	2.203	5.1072	1.3844	14.4992
M059J	GDSC2	2.2489	5.8647	1.074	16.0432
D-502MG	GDSC2	2.279	7.3319	-0.2189	15.906
Onda 10	GDSC2	2.3019	5.4715	0.7304	10.1202
U-251MG	GDSC2	2.4727	5.582	1.4245	13.38
42-MG-BA	GDSC2	2.4767	5.184	1.6182	12.2885
SNB-75	GDSC2	2.4891	4.4578	1.39	5.4321
KNS-81-FD	GDSC2	2.552	5.4376	0.9514	8.0257
U-118MG	GDSC2; CCLE	2.5826	6.1012	1.2766	12.7072
KNS-42	GDSC2; CCLE	2.6263	7.8702	0.2469	15.6929
KALS-1	GDSC2; CCLE	2.6523	6.5443	1.1235	13.2968
T98G	GDSC2; CCLE	2.7417	6.181	1.3841	11.7063
NMC-G1	GDSC2	2.8935	9.7471	-0.9257	17.9099
Becker	GDSC2	2.9091	6.324	1.4643	11.8162
SF268	GDSC2	2.9436	6.4417	1.4366	11.8725
D-542MG	GDSC2	3.217	5.5665	1.3712	3.86
D-263MG	GDSC2	3.4447	5.3392	2.4137	4.9105
ONS-76	GDSC2; CCLE	3.4922	7.0792	1.5833	8.7554
DBTRG-05MG	GDSC2; CCLE	3.5082	7.3194	1.4762	9.2774
SW1088	GDSC2	3.6212	5.9618	2.2423	5.4649
GaMG	GDSC2	3.6577	7.3227	1.594	9.0726
D-392MG	GDSC2	3.9102	7.0822	1.9067	6.7106
SK-MG-1	GDSC2	3.9248	6.97	1.9727	6.3057
Onda 11	GDSC2	3.9376	8.5816	0.4145	8.0196
LN-18	GDSC2; CCLE	3.9843	7.4281	1.7913	6.5973
DK-MG	GDSC2; CCLE	4.0481	5.4987	2.7626	1.5857
PFSK-1	GDSC2	4.1592	11.3737	-0.0292	16.3695
CAS-1	GDSC2; CCLE	4.2759	8.1702	1.6395	6.8006
D-247MG	GDSC2	4.3373	7.1396	1.3129	2.3955
MOG-G-CCM	GDSC2	4.404	8.2114	1.7097	7.4286
LN-229	GDSC2	4.5344	6.444	2.618	1.7548
KS-1 [Human Krukenberg tumour]	GDSC2	4.88	7.493	2.3472	2.5898
LN-405	GDSC2	5.1327	6.6938	2.8022	0.4878
YH-13	GDSC2	5.1912	11.3803	0.7241	10.4027
KINGS-1	GDSC2	6.2088	8.4569	2.5827	0.5395

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TGBC1TKB	GDSC2	4.0491	7.4111	1.8471	7.4099
ETK-1	GDSC2	4.2217	9.3444	1.0237	10.8979
TGBC24TKB	GDSC2	4.8458	7.0885	2.5058	1.8868

Cancer Drug Sensitivity Data Curated from 16 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-59	CCLE	-3.0196	-1.5361	-3.0198	51.6968
HEC-151	CCLE	-1.6287	1.6619	-1.759	40.2057
HEC-265	CCLE	-1.4387	1.3943	-1.5187	38.4281
HEC-6	CCLE	-0.9481	2.4866	-1.1801	34.8428
EFE-184	CCLE	0.0687	3.3259	-0.2936	26.7897
ESS-1	GDSC2	0.1541	1.9413	0.1216	29.0393
TEN	CCLE	1.0215	3.0129	0.8372	17.8231
HEC-251	CCLE	1.2976	3.8526	0.8554	16.6969
HEC-1-B	CCLE	2.3313	5.1271	1.3382	10.8171
MFE-319	GDSC2	3.7812	6.5472	2.0742	6.0524
MFE-296	GDSC2	4.1603	7.5069	1.8803	6.3187
EN	GDSC2; CCLE	4.2762	6.649	2.3705	3.1218
MFE-280	GDSC2; CCLE	4.6914	8.8099	1.6183	6.1456
KLE	GDSC2; CCLE	4.7242	9.1564	1.4744	6.802
RL95-2	GDSC2; CCLE	4.9408	13.0647	-0.275	14.6139
AN3-CA	GDSC2	5.8967	7.5731	2.7801	0.2342

Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
VMRC-RCW	GDSC2; CCLE	-0.701	1.376	-0.7379	31.9432
SW13	GDSC2	0.8567	3.5495	0.5662	23.8747
LB996-RCC	GDSC2	0.9	3.3498	0.6711	23.1801
KTCTL-140	GDSC2	1.0287	3.725	0.3796	16.65
Caki-2	CCLE	1.2749	2.8137	1.1648	15.3069
KMRC-2	CCLE	1.3948	5.5113	0.2432	19.4034
KTCTL-13	GDSC2	1.6379	3.5553	1.0717	10.1578
CAL-54	GDSC2	1.6459	5.9231	0.4531	21.3949
786-O	GDSC2; CCLE	1.6977	4.0258	1.3173	15.3047
Caki-1	GDSC2	1.7687	4.285	0.8483	11.0709
ACHN	GDSC2	1.7894	3.46	1.6098	14.8438
KTCTL-21	GDSC2	1.852	3.8585	1.1339	9.0097
LB2241-RCC	GDSC2	2.0571	3.5431	1.4787	6.1623
UO-31	GDSC2	2.2747	4.3551	1.2657	6.8258
KTCTL-1M	GDSC2	2.3459	4.4124	1.2966	6.4225
SW156	GDSC2	2.3789	4.6823	1.1889	7.0089
BB65-RCC	GDSC2	2.404	5.2594	0.921	8.6284
HA7-RCC	GDSC2	2.5521	4.839	1.2497	6.1482
KMRC-1	GDSC2; CCLE	2.5737	5.967	1.3338	12.4384
KTCTL-26A	GDSC2	2.6899	5.3987	1.0784	6.8631
LB1047-RCC	GDSC2	2.6968	5.4475	1.0595	6.9641
BFTC-909	GDSC2	2.7029	6.1612	1.3584	13.0276
KMRC-20	GDSC2	3.0191	5.4229	2.0095	8.3915
NCC010	GDSC2	3.3276	6.2468	1.1211	5.1249
NCC021	GDSC2	3.3339	6.2159	1.1399	4.9993
RXF 393L	GDSC2	3.4158	6.444	1.0857	5.1553
RCC10RGB	GDSC2	3.5492	6.0243	2.1552	6.1362
KTCTL-195	GDSC2	3.6178	5.7505	2.3446	4.8888
A-498	GDSC2	4.0133	7.3786	1.837	6.875
SN12C	GDSC2	4.0222	7.3728	1.8464	6.803
769-P	GDSC2; CCLE	4.067	8.438	1.3552	8.6721
VMRC-RCZ	GDSC2; CCLE	4.4451	6.2309	2.6624	1.5217
OS-RC-2	GDSC2	4.7681	7.8463	2.1213	3.891
A-704	GDSC2	5.0226	17.1193	-2.2158	22.8494
TK-10	GDSC2	5.7609	7.8907	2.6117	0.6865

Cancer Drug Sensitivity Data Curated from 52 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW403	CCLE	-2.816	0.4941	-2.8782	49.9513
SW480	CCLE	-1.6792	0.688	-1.7068	40.291
COLO 320	CCLE	-1.426	1.1613	-1.4797	38.2228
SK-CO-1	GDSC2	0.1084	2.7937	-0.0563	30.0635
HCC-56	CCLE	0.2015	3.6667	-0.2591	26.1061
SW48	GDSC2; CCLE	0.6542	4.3261	0.0856	24.8184
LS513	GDSC2; CCLE	1.1736	3.8602	0.72	17.8096
NCI-H508	GDSC2	1.4033	6.8888	-0.766	21.7366
SW948	GDSC2	1.9448	12.5011	-2.4604	31.5146
MDST8	GDSC2	2.0249	3.5945	1.8237	12.8107
SW620	GDSC2; CCLE	2.3101	5.963	1.086	14.4727
RKO	GDSC2; CCLE	2.4312	5.8161	1.2723	13.1667
HCT 116	GDSC2; CCLE	2.4407	7.3478	0.5345	16.8504
SNU-283	GDSC2	2.4737	7.673	-0.2282	15.3826
LS180	GDSC2	2.9367	6.0936	1.6033	10.9479
CaR-1	GDSC2	3.1552	4.8687	2.4055	5.7309
SNU-C5	GDSC2	3.1852	7.7531	0.9914	13.6722
RCM-1 [Human ESC]	GDSC2	3.2126	4.8185	2.4807	5.1373
HCT 15	GDSC2; CCLE	3.2341	6.0982	1.86	7.9225
DiFi	GDSC2	3.2454	6.8623	1.4876	10.7384
SNU-175	GDSC2	3.3288	8.0484	0.9644	13.4289
T84	GDSC2; CCLE	3.4204	7.4572	1.3358	10.215
LS411N	GDSC2	3.4355	6.273	1.9399	7.6549
HT-29	GDSC2; CCLE	3.4436	4.9713	2.5963	3.5415
CW-2	GDSC2	3.4448	7.6442	1.2623	11.4778
SW1463	GDSC2	3.4454	7.3937	1.388	10.772
CCK-81	GDSC2	3.5205	6.5592	1.8657	7.8653
COLO 320HSR	GDSC2	3.5355	5.6956	2.308	5.2935
KM12	GDSC2	3.5446	6.3502	1.9891	7.0987
LS123	GDSC2	3.6118	6.011	2.2107	5.6679
GP5d	GDSC2	3.6679	7.6015	1.4632	9.7859
SW837	GDSC2	3.6843	5.9673	2.2878	5.0587
LoVo	GDSC2	3.854	7.5526	1.632	8.3889
SW1417	GDSC2	3.8584	6.9965	1.9103	6.8061
SNU-407	GDSC2	3.8975	7.3333	1.7734	7.4915
COLO205	GDSC2	3.9073	10.2729	0.3214	15.2935
SNU-81	GDSC2	4.244	6.1675	1.6677	0.927
SNU-1040	GDSC2	4.2866	6.2489	1.6547	0.9419
HT115	GDSC2	4.3616	5.8598	1.8324	0.3353
SNU-C2B	GDSC2	4.4534	7.1398	2.2534	3.7222
C2BBe1	GDSC2	4.6437	6.6624	2.5821	1.7837
HT-55	GDSC2	4.6757	7.6085	2.1743	3.766
SW1116	GDSC2	4.7274	6.5969	2.6543	1.3608
NCI-H716	GDSC2	4.7315	10.2235	0.9636	10.1069
LS1034	GDSC2	4.7633	6.4284	2.7421	0.9616
NCI-H747	GDSC2	4.8932	7.6478	2.2856	2.8713
CL-11	GDSC2	4.9487	9.2893	1.5607	6.5253
HCC2998	GDSC2	5.1319	8.079	2.2286	2.8203
COLO 678	GDSC2; CCLE	5.2376	7.214	2.6465	0.8444
SW626	GDSC2	5.5	12.187	0.5469	10.6796
SNU-61	GDSC2	5.7389	7.1336	2.8749	0.1271
SNU-C1	GDSC2	5.9881	7.6672	2.7807	0.2096

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC2	3.1706	6.3657	1.6722	9.8923

Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Hep-G2	CCLE	-2.3051	3.1081	-2.8195	46.3291
HLF	CCLE	-1.9937	-0.5045	-1.9945	42.89
PLC/PRF/5	CCLE	-0.5135	3.1996	-0.8907	31.7671
HLE	GDSC2; CCLE	1.7425	3.5516	1.5305	14.1422
JHH-2	GDSC2; CCLE	2.6133	7.3295	0.7008	15.5435
Hep 3B2.1-7	GDSC2; CCLE	2.9375	6.0859	1.4047	8.7973
JHH-4	GDSC2; CCLE	3.4812	8.5799	0.8244	12.6841
SK-HEP-1	GDSC2; CCLE	3.7357	6.3931	2.1161	5.4236
JHH-1	GDSC2	4.0531	5.5911	2.7233	1.9245
Hep-G2/C3A	GDSC2	4.4257	8.8454	1.4173	8.3189
SNU-398	GDSC2	4.5421	8.1735	1.8222	5.8787
SNU-423	GDSC2	4.7375	12.2313	-0.0151	14.9556
JHH-6	GDSC2; CCLE	4.7819	10.4934	0.868	9.679
HuH-1	GDSC2; CCLE	4.8359	11.0508	0.635	10.695
Huh-7	GDSC2	4.9409	6.5205	2.7868	0.6557
JHH-7	GDSC2	5.2694	14.3562	-0.6684	16.6724
SNU-387	GDSC2	5.8805	9.4523	2.0349	2.7883
SNU-449	GDSC2; CCLE	6.0389	7.813	2.7484	0.2293

Cancer Drug Sensitivity Data Curated from 197 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Lu-99	CCLE	-4.7544	-1.7936	-4.763	66.0053
NCI-H1184	CCLE	-4.5103	-2.2948	-4.5115	64.3627
NCI-H2286	CCLE	-3.7991	-2.2724	-3.7992	58.3873
NCI-H1105	GDSC2	-3.4727	0.3851	-3.5976	57.2212
NCI-H1876	GDSC2	-3.3004	1.4024	-3.4861	58.8495
NCI-H209	GDSC2	-2.6009	0.651	-2.654	53.82
NCI-H1339	CCLE	-2.5914	-0.4984	-2.5968	48.0291
NCI-H526	GDSC2	-2.5743	1.6748	-2.7495	53.3518
IST-SL2	GDSC2	-2.1016	1.8789	-2.2745	49.5115
RERF-LC-A1	CCLE	-1.7913	1.8781	-1.9708	41.7054
COLO 677	CCLE	-1.6706	0.8685	-1.7105	40.2612
COR-L279	GDSC2	-1.404	1.9348	-1.5338	47.613
NCI-H322	CCLE	-1.3185	0.6144	-1.3314	37.1417
NCI-H1734	GDSC2	-1.0869	1.3215	-1.1806	34.6601
HCC4006	CCLE	-0.7755	2.8379	-1.0771	33.6617
Lu-134-A	GDSC2	-0.6774	2.5856	-1.0269	31.8188
COLO 699	CCLE	-0.5693	3.7337	-1.1178	32.9036
NCI-H2030	GDSC2; CCLE	-0.5507	1.7885	-0.624	30.8099
NCI-H2009	GDSC2; CCLE	-0.5453	3.0852	-0.8363	33.4861
EBC-1	GDSC2; CCLE	-0.5343	3.25	-0.8671	33.5554
NCI-H3255	GDSC2; CCLE	-0.4531	1.7533	-0.5156	29.9257
NCI-H748	GDSC2	-0.3652	2.1449	-0.5642	27.9878
HCC78	GDSC2	-0.3515	1.3268	-0.3638	33.5573
DMS 79	GDSC2	-0.0275	2.7847	-0.3819	25.4447
LC-2/ad	GDSC2	0.056	2.3394	-0.1557	23.8488
GLC-82	CCLE	0.1421	3.5586	-0.2876	26.4694
SBC-3	GDSC2	0.2511	4.9743	-0.5906	31.7251
NCI-H2081	GDSC2	0.3634	4.1878	-0.5074	24.3893
NCI-H1694	GDSC2; CCLE	0.4096	2.4806	0.3275	24.6887
NCI-H1341	GDSC2; CCLE	0.4675	2.3372	0.4101	24.0986
NCI-H1648	GDSC2	0.4807	4.3835	-0.122	31.4711
NCI-H460	GDSC2	0.5296	2.231	0.39	18.718
NCI-H1781	GDSC2	0.6008	2.9432	0.4464	25.5417
HCC2935	CCLE	0.6761	4.4983	-0.059	23.3754
NCI-H1155	GDSC2	0.6915	2.1573	0.6662	24.1057
NCI-H211	GDSC2; CCLE	0.7258	4.5211	0.09	24.5326
NCI-H1373	CCLE	0.7468	4.6186	-0.0332	22.9949
COR-L32	GDSC2	0.8224	4.0877	0.3524	25.0622
Calu-1	CCLE	0.9165	6.1218	-0.5151	24.5996
NCI-H2110	GDSC2	0.9401	4.4441	-0.033	19.4096
NCI-H1623	GDSC2	0.9702	3.6395	0.6621	22.9319
NCI-H2171	GDSC2	0.9822	3.0035	0.6301	15.3782
SBC-5	GDSC2; CCLE	1.013	1.8266	1.0115	19.3025
NCI-H2795	GDSC2	1.0269	4.1397	0.5545	23.2348
NCI-H2196	GDSC2	1.0335	5.6784	-0.5221	21.7924
NCI-H2122	GDSC2; CCLE	1.0721	6.8553	-0.5482	26.0567
NCI-H146	GDSC2	1.0725	4.5063	0.0701	18.3015
NCI-H292	GDSC2	1.1808	3.0395	0.8271	13.41
COR-L311	GDSC2	1.1915	5.245	0.2899	23.8984
NCI-H1048	GDSC2; CCLE	1.2759	4.134	0.8244	19.1432
NCI-H2227	GDSC2	1.4178	10.6896	-2.6373	29.453
NCI-H2170	GDSC2; CCLE	1.4209	2.9986	1.3257	16.2983
PaCa-3	GDSC2	1.5151	5.0833	0.6946	22.6563
NCI-H64	GDSC2	1.5687	3.2319	1.4324	18.3084
COLO 668	GDSC2	1.5713	3.7119	1.2923	17.3278
NCI-H647	GDSC2	1.6532	4.7159	0.5304	13.4317
T3M-10	CCLE	1.6896	8.8545	-1.0801	24.4467
NCI-H510A	GDSC2	1.6925	5.1533	0.3527	14.3856
EMC-BAC-1	GDSC2	1.741	4.0928	0.9155	10.7496
NCI-H2810	GDSC2	1.7811	4.4277	0.7902	11.3894
COR-L303	GDSC2	1.7832	6.6974	-0.3295	18.0933
RERF-LC-MS	GDSC2	1.8362	4.3246	0.8917	10.5713
NCI-H847	GDSC2	1.8902	5.9643	0.6767	21.2494
SHP-77	GDSC2; CCLE	1.9311	4.6746	1.3009	14.5836
NCI-H82	GDSC2	1.933	4.551	1.3557	15.6117
ABC-1	GDSC2	1.9352	4.1275	1.0796	9.0665
NCI-H290	GDSC2	2.0089	4.4837	0.9702	9.5118
NCI-H1651	GDSC2	2.0098	5.7961	0.8732	17.9313
NCI-H1703	GDSC2	2.0483	4.1801	1.6305	15.1
NCI-H740	GDSC2	2.0753	7.1114	-0.2813	16.8845
LOU-NH91	GDSC2; CCLE	2.0856	6.9281	0.4074	18.5075
NCI-H1437	GDSC2	2.0937	5.2676	0.6548	11.221
NCI-H2804	GDSC2	2.1069	6.0974	0.2521	13.6589
NCI-H2228	GDSC2; CCLE	2.2215	6.9638	0.5186	17.5637
IST-SL1	GDSC2	2.2498	6.0903	0.3773	12.4624
DMS 53	GDSC2	2.2632	4.9516	1.5159	13.5718
NCI-H2373	GDSC2	2.351	5.9059	1.1526	15.2787
SK-LU-1	GDSC2; CCLE	2.3922	8.385	-0.0208	19.6188
NCI-H2087	GDSC2	2.4373	6.312	1.038	15.6293
COR-L321	GDSC2	2.4662	5.3117	0.9455	8.299
NCI-H727	GDSC2; CCLE	2.4722	7.6329	0.423	17.3032
NCI-H2023	GDSC2	2.4844	4.3757	1.9998	10.1549
HCC366	GDSC2	2.512	5.5132	0.8818	8.5725
NCI-H3122	GDSC2	2.5578	5.8704	1.3658	13.4361
NCI-H2444	GDSC2; CCLE	2.6015	5.4151	1.4461	9.4652
HARA [Human squamous cell lung carcinoma]	GDSC2	2.705	6.3992	1.2431	13.6658
NCI-H69	GDSC2	2.7341	6.3741	1.282	14.6751
NCI-H2172	GDSC2; CCLE	2.7427	5.2779	1.6401	8.0343
LB647-SCLC	GDSC2	2.7456	5.4177	1.1114	6.5153
SW1271	GDSC2; CCLE	2.7546	6.2168	1.3782	11.701
NCI-H1836	GDSC2	2.7901	5.3491	1.1786	5.985
NCI-H250	GDSC2	2.8072	5.8367	0.9508	7.3616
NCI-H2461	GDSC2	2.8103	7.05	1.016	14.607
HOP-62	GDSC2	2.8466	6.423	1.3594	12.5911
BEN	GDSC2	2.8751	7.7652	0.0465	12.6797
NCI-H1792	GDSC2	2.9087	5.0566	2.09	8.2616
A-549	GDSC2; CCLE	2.9251	5.288	1.9913	8.0396
CAL-12T	GDSC2	2.9648	6.3243	0.8279	7.7317
Lu-135	GDSC2	2.9903	6.4342	1.4815	11.4839
NCI-H2803	GDSC2	3.0038	5.3265	1.343	4.4736
SW1573	GDSC2	3.0142	6.4478	1.4957	11.3353
KNS-62	GDSC2	3.0309	6.7785	1.3455	12.1359
Calu-6	GDSC2	3.0352	8.3541	0.5631	16.382
Lu-139	GDSC2	3.1467	8.3385	-0.0297	12.4118
NCI-H1770	GDSC2	3.1634	5.9973	1.1295	5.4228
NCI-H838	GDSC2	3.1871	6.0544	1.1183	5.4392
SBC-1	GDSC2	3.2433	7.8243	0.2957	10.2731
NCI-H810	GDSC2; CCLE	3.2606	8.3773	0.743	13.6304
NCI-H1963	GDSC2	3.2647	6.618	1.6259	9.9004
DMS 273	GDSC2	3.2714	6.8356	1.5228	10.4687
NCI-H1666	GDSC2; CCLE	3.2803	10.6033	-0.3536	18.7136
NCI-H2029	GDSC2	3.3116	5.9256	1.263	4.3126
NCI-H1581	GDSC2	3.3172	7.847	1.0554	12.9621
NCI-H1693	GDSC2; CCLE	3.3696	7.8026	1.1212	11.4452
LXF 289	GDSC2	3.4131	5.8032	2.1564	6.4691
COR-L105	GDSC2	3.4204	5.665	2.2314	6.0195
SK-MES-1	GDSC2	3.442	8.039	1.0627	12.5909
NCI-H650	GDSC2	3.4605	7.291	1.4516	10.3739
NCI-H2135	GDSC2	3.4632	6.0685	1.2928	3.8479
NCI-H345	GDSC2	3.486	4.534	1.971	0.3998
NCI-H1944	GDSC2	3.4924	8.1214	1.0627	12.459
LC-1/sq	GDSC2	3.5448	7.2345	1.5482	9.6127
EPLC-272H	GDSC2	3.5607	8.0503	1.1537	11.7823
HCC33	GDSC2	3.5771	5.5657	1.588	2.0259
NCI-H23	GDSC2	3.5895	7.4031	1.4998	9.7741
HCC44	GDSC2	3.5922	6.2139	2.0945	6.3793
NCI-H2591	GDSC2	3.5951	6.6155	1.8969	7.5021
NCI-H1436	GDSC2	3.6107	5.8297	1.4899	2.4948
LCLC-97TM1	GDSC2	3.6229	9.1737	0.6429	14.3731
EMC-BAC-2	GDSC2	3.6269	7.3567	1.5527	9.382
Lu-65	GDSC2	3.6372	11.0197	-0.2675	18.7865
NCI-H513	GDSC2	3.6536	7.2019	1.651	8.7599
PC-14	GDSC2	3.658	6.7287	1.8898	7.3902
NCI-H1869	GDSC2; CCLE	3.6886	6.0246	2.2627	4.7578
NCI-H524	GDSC2	3.7114	11.2391	-0.3169	18.8155
NCI-H1915	GDSC2; CCLE	3.7134	9.3699	0.6176	13.1629
NCI-H2291	GDSC2	3.7252	8.1179	0.4936	8.0082
Lu-99A	GDSC2	3.7305	9.5864	0.5233	14.7173
NCI-H2869	GDSC2	3.7383	6.6762	1.1814	3.9913
HOP-92	GDSC2	3.7585	6.9828	1.8413	7.4278
NCI-H2141	GDSC2	3.8308	10.1593	0.3175	15.5047
NCI-H2731	GDSC2	3.9099	6.0556	2.4087	3.8895
IA-LM	GDSC2; CCLE	3.9184	6.2065	2.3414	3.8922
COR-L88	GDSC2	3.9295	7.7517	1.5907	9.2764
Ms-1	GDSC2	3.9395	9.2757	0.8428	12.5276
NCI-H2818	GDSC2	3.9444	5.9132	2.5011	3.3094
NCI-H446	GDSC2	3.9569	9.8235	0.584	13.8404
COR-L23	GDSC2; CCLE	4.0097	8.307	1.3768	8.6817
NCI-H1755	GDSC2	4.0167	6.8743	2.0861	5.4703
RERF-LC-Sq1	GDSC2	4.0235	8.9094	1.0892	11.0023
A-427	GDSC2	4.0746	12.2893	-1.2872	16.6336
NCI-H2369	GDSC2	4.1187	6.0639	2.5444	2.7544
NCI-H841	GDSC2	4.1661	6.2621	2.4817	3.0063
HCC827	GDSC2	4.1671	8.0111	1.6389	7.6478
NCI-H1688	GDSC2	4.1728	6.5317	2.3587	4.0228
VMRC-LCD	GDSC2	4.1814	6.0956	2.5691	2.5181
NCI-H1568	GDSC2	4.1892	10.973	0.1929	15.236
Lu-165	GDSC2	4.2301	8.3332	1.527	8.1322
NCI-H1975	GDSC2; CCLE	4.2344	9.3117	1.0493	9.8738
NCI-H2722	GDSC2	4.2875	7.6447	1.9027	5.9348
NCI-H1993	GDSC2	4.2972	7.4927	1.9827	5.4748
NCI-H520	GDSC2; CCLE	4.3176	11.6235	-0.0311	14.8533
RERF-LC-KJ	GDSC2	4.3464	7.9608	1.7909	6.4326
NCI-H835	GDSC2	4.3952	18.4936	-3.389	28.8678
NCI-H1793	GDSC2	4.3981	7.3566	2.1156	4.5582
NCI-H441	GDSC2; CCLE	4.4334	9.7252	0.9927	9.7502
NCI-H2085	GDSC2	4.4534	6.5998	2.5024	2.4328
NCI-H226	GDSC2	4.4723	6.0624	2.75	1.2253
NCI-H2405	GDSC2	4.4925	8.2982	1.7288	6.482
UMC-11	GDSC2	4.5184	13.378	-0.7471	18.6779
NCI-H358	GDSC2	4.5424	9.814	1.0283	10.1653
CPC-N	GDSC2	4.5492	8.4641	1.6878	6.5949
NCI-H596	GDSC2	4.5594	6.9734	2.3954	2.8135
NCI-H1092	GDSC2; CCLE	4.6384	13.1899	-0.5625	16.4527
DMS 114	GDSC2	4.6824	7.6394	2.1641	3.8076
NCI-H2347	GDSC2	4.713	7.1927	2.3861	2.8968
NCI-H661	GDSC2; CCLE	4.7283	7.4477	2.2798	2.8794
NCI-H1650	GDSC2	4.7317	7.0837	2.4454	2.3171
LCLC-103H	GDSC2; CCLE	4.7906	9.4284	1.389	7.1066
HCC15	GDSC2	4.8384	9.3505	1.4586	7.272
NCI-H1563	GDSC2	4.879	6.6639	2.7012	1.0167
EKVX	GDSC2	4.9227	7.6017	1.4066	1.3695
NCI-H1838	GDSC2	4.9603	10.4487	1.0143	10.2387
ChaGo-K-1	GDSC2	5.0553	6.6194	1.8209	0.152
NCI-H322M	GDSC2	5.13	10.9333	0.8973	9.6454
NCI-H1435	GDSC2	5.1736	6.5878	2.8579	0.3215
NCI-H2066	GDSC2	5.1825	7.0236	2.6968	0.8666
NCI-H720	GDSC2	5.185	6.5233	2.8856	0.2549
LK-2	GDSC2	5.2389	12.0766	0.4209	11.8076
NCI-H2595	GDSC2	5.2734	7.8307	2.4112	1.8193
NCI-H196	GDSC2	5.2816	6.9924	2.7514	0.5513
Calu-3	GDSC2	5.4727	8.0174	2.4321	1.5321
NCI-H1573	GDSC2	5.4831	6.9461	2.8476	0.2552
NCI-H2342	GDSC2	5.5623	7.7478	2.5815	0.998
NCI-H1355	GDSC2	5.8321	7.9422	2.6217	0.6193
NCI-H522	GDSC2; CCLE	6.2639	16.2544	-0.8871	14.5951
NCI-H1299	GDSC2	6.9811	22.3216	-3.328	22.218

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC2	2.8281	5.5439	1.7766	10.2864

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYSE-30	CCLE	-0.2461	3.7699	-0.7791	30.1753
TE-15	GDSC2	0.6231	3.1795	0.1793	19.4764
OE33	GDSC2; CCLE	1.4573	5.1281	0.6155	19.506
KYSE-270	GDSC2	2.0946	3.9952	1.7532	12.9022
TE-11	GDSC2	2.3347	4.8871	1.0499	8.0143
KYSE-510	GDSC2	2.4465	3.6139	1.7766	3.1073
TE-10	GDSC2	2.5783	4.477	1.4498	4.8197
TE-5	GDSC2	3.0292	6.1037	1.6802	10.2434
EC-GI-10	GDSC2	3.1479	7.1432	1.2644	12.2631
T.T	GDSC2	3.3795	5.4342	2.3134	6.2197
OE21	GDSC2; CCLE	3.465	5.0709	2.5637	3.6648
TE-8	GDSC2	3.473	7.2681	1.4733	10.2191
TE-6	GDSC2	3.5328	5.1793	2.5626	3.8428
KYSE-450	GDSC2	3.5637	7.8099	1.2761	11.0952
KYSE-180	GDSC2	3.6655	6.4435	2.0374	6.5302
KYSE-150	GDSC2	3.7227	9.9893	0.316	17.1525
TE-9	GDSC2; CCLE	3.8111	6.7989	1.9724	6.0146
TE-1	GDSC2	3.9512	8.1624	1.404	9.4398
KYSE-410	GDSC2; CCLE	3.988	6.6921	2.1545	4.7177
KYSE-520	GDSC2; CCLE	4.3831	7.0553	2.2482	3.5484
COLO 680N	GDSC2	4.4886	9.6601	1.0647	10.0875
TE-4	GDSC2	4.5264	7.6527	2.0592	4.6288
OE19	GDSC2	5.1298	9.3393	1.6533	5.7213
KYSE-70	GDSC2	5.5334	8.5403	2.2437	2.2611
KYSE-140	GDSC2	6.2552	10.2025	1.9093	2.9168

Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEY A8	CCLE	-2.5831	-0.5897	-2.587	47.9559
OC 315	CCLE	-1.8679	-0.4079	-1.8688	41.8099
OC 316	CCLE	-1.6614	-0.4623	-1.6616	40.0339
ONCO-DG-1	CCLE	-0.7613	1.2613	-0.7917	32.4332
FU-OV-1	GDSC2; CCLE	-0.684	3.5843	-1.1242	35.1542
MCAS	CCLE	-0.6536	3.3524	-1.0888	33.1633
EFO-27	GDSC2; CCLE	-0.5594	0.7297	-0.5621	30.5808
TYK-nu	GDSC2; CCLE	0.3358	4.7889	-0.4288	28.2498
COV318	CCLE	0.3681	3.3949	0.0109	24.2192
Caov-3	GDSC2	0.4689	2.5263	0.2404	19.8098
OC 314	GDSC2	0.5912	1.8285	0.5825	27.4467
Caov-4	GDSC2	0.7216	4.1508	0.2213	28.6658
OVSAHO	CCLE	0.7583	5.488	-0.3914	24.6078
OVCAR-8	GDSC2; CCLE	1.0166	6.0384	-0.2353	24.928
A2780	GDSC2; CCLE	1.3492	5.4365	0.3703	21.037
TOV-112D	GDSC2; CCLE	1.3629	2.9021	1.2822	16.7186
OVMANA	CCLE	1.3793	11.0948	-2.4664	30.171
ES-2	GDSC2	1.5532	5.0768	0.7368	20.2753
DOV13	GDSC2; CCLE	1.9076	3.3947	1.758	12.4794
JHOS-2	GDSC2	2.2001	7.4437	-0.3412	16.8347
OVK18	GDSC2	2.2586	10.2556	-1.6979	23.3069
JHOS-4	GDSC2	2.5394	8.561	-0.6183	17.3317
SK-OV-3	GDSC2; CCLE	3.1925	6.579	1.5843	9.4746
OAW28	GDSC2	3.2785	7.4543	1.2194	12.1578
OAW42	GDSC2	3.426	7.8498	1.1441	12.1838
IGROV-1	GDSC2; CCLE	3.5182	11.5713	-0.6404	19.3323
EFO-21	GDSC2; CCLE	3.5337	5.1519	2.5769	3.4447
OV56	GDSC2	3.5348	4.9509	2.6774	3.1829
RMG-I	GDSC2	3.578	5.6344	2.3715	5.3127
OV-90	GDSC2; CCLE	3.7553	6.4672	2.0942	5.4966
OVCAR-3	GDSC2; CCLE	3.9151	6.6506	2.1223	5.0256
OVKATE	GDSC2	4.3279	7.8847	1.8148	6.9659
TOV-21G	GDSC2; CCLE	4.6867	12.5537	-0.2118	14.8636
OVISE	GDSC2	4.9982	6.2528	2.9112	0.2694
OVTOKO	GDSC2; CCLE	5.0042	11.9432	0.3202	11.8413
OVCAR-4	GDSC2; CCLE	5.3311	12.8051	0.1325	12.0676
OVCAR-5	GDSC2	5.723	8.1308	2.5028	1.0591
Kuramochi	GDSC2; CCLE	5.9248	8.0245	2.6287	0.5076

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
L3.3	CCLE	-3.7706	-2.2873	-3.7706	58.1431
PL45	CCLE	-1.9942	0.1032	-2.0043	42.9272
PK-1	CCLE	-1.5167	2.1019	-1.7162	39.4874
PK-45H	CCLE	0.2848	4.2204	-0.3674	26.2683
PK-59	CCLE	0.4175	4.4441	-0.3117	25.508
KP-1NL	CCLE	0.826	3.5526	0.4564	20.3703
CFPAC-1	GDSC2	1.6114	5.0126	0.8246	19.5414
Capan-1	GDSC2	1.6443	6.1815	0.3324	21.9413
KP-4	GDSC2; CCLE	1.7463	3.9445	1.3997	14.7407
HuP-T4	GDSC2	2.0812	4.6004	1.4879	14.319
PSN1	GDSC2	2.1213	5.1448	1.2854	15.2729
MIA PaCa-2	GDSC2; CCLE	2.625	5.6622	1.5302	11.2789
YAPC	GDSC2	2.8071	5.0085	2.0188	8.9505
Panc 10.05	GDSC2; CCLE	2.8086	4.9953	2.0266	8.1837
Panc 02.03	GDSC2; CCLE	2.8332	6.6059	1.2568	12.115
PL4	GDSC2	3.1269	7.9563	0.8403	14.6103
MZ-PC-1	GDSC2	3.187	6.4116	0.9455	6.4666
Panc 03.27	GDSC2; CCLE	3.3317	5.7819	2.1001	6.4187
SUIT-2	GDSC2; CCLE	3.3452	8.6785	0.663	13.8192
DAN-G	GDSC2	3.5523	5.4315	2.4525	4.4124
KP-1N	GDSC2; CCLE	3.7325	6.4667	2.0773	5.6328
BxPC-3	GDSC2	3.9883	6.5463	2.2257	4.7342
SW1990	GDSC2	4.0522	6.4033	2.3392	3.9784
HPAF-II	GDSC2	4.0586	7.2565	1.9296	6.2381
PaTu 8902	GDSC2	4.092	7.3098	1.9276	6.1789
Hs 766T	GDSC2; CCLE	4.2665	6.1963	2.5748	2.1545
AsPC-1	GDSC2; CCLE	4.3789	7.4877	2.0404	4.5844
HuP-T3	GDSC2; CCLE	4.4635	9.7798	0.9879	9.7137
PaTu 8988t	GDSC2	4.4711	8.0503	1.8333	5.9354
Panc 04.03	GDSC2; CCLE	4.5876	8.8317	1.5371	6.7349
QGP-1	GDSC2	4.8561	13.115	-1.1366	14.2014
HPAC	GDSC2; CCLE	4.8791	10.7461	0.8139	9.7558
SU.86.86	GDSC2	5.3227	6.9413	2.7874	0.4288
Panc 08.13	GDSC2	5.4935	7.1424	2.7812	0.3677
KP-2	GDSC2; CCLE	5.5636	11.2272	1.0449	7.4527
Capan-2	GDSC2; CCLE	5.5761	8.0339	2.4744	1.1697
KP-3	GDSC2; CCLE	6.1973	8.293	2.6377	0.3818

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
IST-Mes2	CCLE	-3.8083	-2.3773	-3.8083	58.4678
NCI-H2452	GDSC2; CCLE	0.5346	4.492	-0.104	26.1063
IST-Mes1	GDSC2; CCLE	2.1723	12.0551	-2.0362	27.9156
MSTO-211H	GDSC2	2.7206	5.9065	1.4997	12.1796
NCI-H2052	GDSC2	3.1361	5.5204	2.0643	7.7424
MPP 89	GDSC2; CCLE	3.6765	8.5599	0.9922	11.3798
NCI-H28	GDSC2	3.8476	5.3411	2.7096	2.3523

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
LNCaP clone FGC	GDSC2	1.7621	5.9297	0.566	20.4047
DU145	GDSC2; CCLE	2.1164	3.4512	1.9688	10.729
22Rv1	GDSC2; CCLE	2.3812	5.3495	1.4469	12.4245
NCI-H660	GDSC2	3.3934	5.264	1.6188	2.136
PC-3	GDSC2; CCLE	3.4111	6.8035	1.6549	8.571
VCaP	GDSC2	4.3394	8.1005	1.7183	6.8465

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
A-253	GDSC2	3.7111	7.9543	1.3215	10.4731

Cancer Drug Sensitivity Data Curated from 71 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Hs 944.T	CCLE	-3.4539	-1.0709	-3.4595	55.3741
HMCB	CCLE	-2.1731	1.2204	-2.2779	44.6863
WM88	CCLE	-2.1102	1.8315	-2.3069	44.3567
IGR-39	CCLE	-1.6189	1.114	-1.6781	39.8877
Hs 294T	CCLE	-1.48	1.2696	-1.5479	38.7358
K029AX	CCLE	-1.4449	2.6439	-1.7584	39.2463
MDA-MB-435S	CCLE	-1.1276	2.5434	-1.3886	36.4542
Hs 695T	CCLE	-0.6674	3.3365	-1.099	33.2639
WM1799	CCLE	0.2772	4.693	-0.5589	27.1427
A2058	GDSC2; CCLE	0.4418	3.4352	0.1471	25.3529
Malme-3M	CCLE	0.5356	5.3244	-0.55	26.126
SK-MEL-30	GDSC2; CCLE	0.5507	4.5933	-0.2297	24.6329
A-375	GDSC2; CCLE	0.6386	2.8667	0.5041	23.0045
MZ-MEL-2	GDSC2	0.7778	4.4613	-0.204	21.0222
Hs 936.T	CCLE	0.8372	4.4227	0.1417	21.8349
WM793	GDSC2; CCLE	0.9494	5.4516	-0.0496	24.3479
Mel Ho	GDSC2; CCLE	0.9582	3.8798	0.482	19.7539
SK-MEL-5	GDSC2; CCLE	0.9588	4.4775	0.2476	20.8863
SK-MEL-24	GDSC2; CCLE	1.0377	4.3971	0.4707	21.6542
IST-MEL1	GDSC2	1.253	3.7283	0.9413	22.4238
DJM-1	GDSC2	1.3051	3.6643	0.6885	13.7337
WM983B	CCLE	1.3882	3.9212	0.9253	16.027
A-388	GDSC2	1.4681	5.0592	0.1897	16.144
SK-MEL-31	GDSC2; CCLE	1.5248	4.3594	0.8886	15.7305
Hs 940.T	GDSC2	1.8763	4.9331	0.6286	12.0764
A-431	GDSC2	1.8871	5.7588	0.2289	14.4936
SF8657	CCLE	1.9251	6.4546	0.3116	17.3779
G-mel	GDSC2	1.9298	4.6747	0.8047	10.8051
WT2-iPS	GDSC2; CCLE	2.0045	4.7249	1.3548	14.0751
LOX-IMVI	GDSC2	2.0434	8.1062	-0.2044	23.2008
UACC-62	GDSC2	2.0504	6.6589	0.5034	19.7354
RPMI-7951	GDSC2	2.0781	4.9407	1.3344	15.2056
COLO 800	GDSC2	2.1496	5.5302	0.572	11.5648
IPC-298	GDSC2; CCLE	2.2675	3.3205	2.0949	7.0986
IGR-37	GDSC2; CCLE	2.3028	4.882	1.5874	11.9544
SK-MEL-28	GDSC2	2.3861	8.1898	-0.5588	17.465
Hs 938.T	GDSC2	2.5047	6.7078	0.2794	12.3153
SK-MEL-2	GDSC2; CCLE	2.6086	3.6638	2.4292	6.7808
MZ-MEL-7	GDSC2	2.6199	4.5961	1.4226	4.884
MeWo	GDSC2; CCLE	2.6226	4.2803	2.1827	7.9469
M14	GDSC2	2.6226	6.2548	1.2385	13.9431
Hs 852.T	CCLE	2.7979	7.1979	0.7303	12.7539
RVH-421	GDSC2; CCLE	2.8806	6.6014	1.0989	10.5862
MMAc-SF	GDSC2	2.9169	6.846	0.5345	9.6518
CP50-MEL-B	GDSC2	2.9275	6.3424	0.7913	8.0492
SK-MEL-3	GDSC2	3.053	7.4487	0.3394	10.4855
COLO 783	GDSC2	3.0583	4.7047	1.674	2.3907
WM278	GDSC2	3.0685	6.4241	1.5549	10.8453
COLO 679	GDSC2; CCLE	3.0811	5.1572	2.1966	6.5436
A101D	GDSC2	3.2843	7.3137	1.2946	11.7217
CP66-MEL	GDSC2	3.4898	6.0943	1.2974	3.7726
VMRC-MELG	GDSC2	3.5146	15.7501	-3.426	26.0013
UACC-257	GDSC2	3.6618	6.5483	1.9825	6.8526
COLO 829	GDSC2	3.8145	8.1233	1.3184	10.2391
WM35	GDSC2	3.8339	7.7312	1.528	9.9056
IGR-1	GDSC2	3.8905	7.7722	1.5511	8.7589
LB2518-MEL	GDSC2	3.9637	7.6594	0.8657	5.3802
SH-4	GDSC2	4.0084	7.9742	1.5402	8.5494
SK-MEL-1	GDSC2	4.0097	8.9435	1.0617	12.236
HT-144	GDSC2; CCLE	4.0327	10.6316	0.2413	14.2365
Mel JuSo	GDSC2	4.0491	8.1694	1.4743	8.8241
CHL-1	GDSC2; CCLE	4.3726	8.7634	1.4193	7.7314
WM115	GDSC2	4.5404	8.8161	1.5121	7.567
LB373-MEL-D	GDSC2	4.8521	16.0822	-2.5805	20.1449
451Lu	GDSC2	4.8581	7.0523	1.5911	0.7609
GAK	GDSC2	5.0058	6.2694	2.9081	0.2734
HMV-II	GDSC2	5.3415	14.1316	-0.5062	15.8364
WM1552C	GDSC2	5.9776	7.5528	2.8162	0.159
COLO 792	GDSC2	6.1827	10.8378	1.5953	4.4241
G-361	GDSC2; CCLE	6.339	16.9841	-1.1875	15.5924
EquiPSC Line K2	GDSC2	3.7662	8.3917	0.39	8.522

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC2	0.5851	5.9113	-1.0669	26.3012

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE 617.T	CCLE	-3.7012	-0.0489	-3.7592	57.0905
EW-8	GDSC2	-0.6216	1.4792	-0.652	36.0985
Hs 633.T	GDSC2	-0.156	1.6995	-0.183	35.0341
KYM-1	GDSC2	0.3996	2.5221	0.3101	27.0665
MFH-ino	GDSC2	0.9977	4.0466	0.5562	25.6582
SW982	GDSC2	1.1652	4.6828	0.4949	22.9836
STS-0421	GDSC2	1.2688	6.585	-0.7403	22.0815
TE 441.T	GDSC2	1.3061	4.6432	0.2349	16.4557
VA-ES-BJ	GDSC2	1.714	4.6351	1.0919	17.8195
G-401	GDSC2; CCLE	1.7833	4.6504	1.1578	15.7791
SW872	GDSC2	1.858	3.4463	1.6887	14.1679
SK-LMS-1	GDSC2	2.2288	6.7665	0.6212	18.5345
GCT	GDSC2; CCLE	2.3357	7.8873	0.173	18.8846
G-402	GDSC2	2.3958	7.106	0.6118	18.0472
SK-UT-1	GDSC2	2.5962	5.8376	1.4178	13.0246
A-204	GDSC2; CCLE	2.995	7.6186	0.8954	13.5393
MES-SA	GDSC2	3.2846	6.3341	1.7846	8.9401
Rh41	GDSC2	3.2848	9.3079	0.298	17.0383
HT-1080	GDSC2	4.0894	6.0376	2.538	2.84
RKN	GDSC2; CCLE	4.1164	6.426	2.3716	3.3822
Rh30	GDSC2	4.3205	7.8773	1.8132	6.3619
SW684	GDSC2	4.7561	6.1571	2.8472	0.5831
RD	GDSC2	5.8687	12.8255	0.4881	10.2747

Cancer Drug Sensitivity Data Curated from 33 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
AZ-521	CCLE	-3.5842	0.5585	-3.6956	55.962
HSC-39	GDSC2	-0.5223	3.7692	-1.0036	40.305
BGC-823	CCLE	-0.0084	3.6115	-0.4685	27.8753
NUGC-3	GDSC2; CCLE	0.2018	2.8302	0.0374	26.7798
SNU-5	GDSC2	0.3679	1.9453	0.3448	27.0468
SH-10-TC	CCLE	0.9724	3.0484	0.7738	18.3108
MKN74	CCLE	1.0838	3.2067	0.8489	17.5261
TGBC11TKB	GDSC2	1.1672	3.1732	1.0093	20.4018
RF-48	GDSC2	1.2145	5.6015	0.1597	24.4433
OCUM-1	GDSC2; CCLE	1.4342	6.5485	-0.046	22.6737
SNU-16	GDSC2	1.6914	4.3567	1.1822	19.171
MKN45	GDSC2; CCLE	1.9875	6.9804	0.2889	19.371
ECC10	GDSC2	2.5252	6.2208	1.1648	14.6548
23132/87	GDSC2	2.6076	6.5759	1.067	14.9378
AGS	GDSC2	2.6219	6.2487	1.2408	13.9326
HGC-27	GDSC2; CCLE	2.6837	6.7795	1.0362	13.6566
SNU-1	GDSC2	2.8039	5.7429	1.6566	11.0404
TMK-1	GDSC2	3.0999	7.6157	0.2921	10.6491
SCH	GDSC2	3.2167	6.7227	0.8153	7.213
ECC12	GDSC2	3.3231	8.0444	0.2462	10.3719
Fu97	GDSC2	3.4972	12.3656	-1.0547	24.0472
RERF-GC-1B	GDSC2	3.5958	6.4289	1.9903	6.9667
SK-GT-2	GDSC2	3.917	6.7377	2.081	5.712
GCIY	GDSC2	4.2032	6.3648	2.4573	3.0716
NCI-N87	GDSC2	4.302	6.8982	2.2698	3.901
MKN1	GDSC2	4.7754	7.8275	2.1343	3.8117
Hs 746.T	GDSC2	5.0036	11.4444	0.5625	11.5916
IM95	GDSC2	5.1797	9.0726	1.8078	4.8428
KATO III	GDSC2	5.3126	7.8439	2.4253	1.7179
MKN7	GDSC2; CCLE	5.3369	7.6835	2.5036	1.2597
NUGC-4	GDSC2	5.6349	8.1185	2.4677	1.2526
MKN28	GDSC2	6.3651	9.1378	2.3919	0.9883
SNG-M	GDSC2; CCLE	3.8168	5.4571	2.6333	2.5932

Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW579	CCLE	-2.4317	-1.2935	-2.4317	46.6485
IHH-4	GDSC2	1.2232	2.5716	1.1843	19.3201
CAL-62	GDSC2	1.5522	3.5936	1.3101	17.3148
FTC-133	GDSC2	2.3187	3.9051	2.0267	10.6145
8505C	GDSC2; CCLE	2.3338	6.5615	0.8196	15.7457
ML-1 [Human leukemia]	GDSC2	2.5052	4.2444	1.5088	4.6392
CGTH-W-1	GDSC2	2.7864	4.7557	2.1213	9.3163
KMH-2	GDSC2	3.2378	6.0615	1.1494	5.143
BHT-101	GDSC2	3.2673	7.2736	1.3004	11.7352
TT2609-C02	GDSC2; CCLE	3.2831	6.6173	1.6418	8.9485
B-CPAP	GDSC2; CCLE	3.4614	9.4084	0.3941	14.8465
ASH-3	GDSC2	3.5659	6.3466	2.0078	6.9397
HTC-C3	GDSC2	3.838	6.4111	2.1835	5.3062
K5	GDSC2	3.8726	7.7214	1.5626	8.7361
8305C	GDSC2; CCLE	3.9917	11.7793	-0.3623	17.0378
WRO	GDSC2	5.2166	7.4417	2.5449	1.3226
TT	GDSC2	5.7364	7.148	2.8692	0.1487

Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SAS	GDSC2	-0.35	1.3099	-0.3616	33.5399
BB30-HNC	GDSC2	0.289	2.2995	0.1094	21.3444
FaDu	GDSC2	0.3963	2.9918	0.2128	27.5389
HSC-2	GDSC2; CCLE	0.5204	2.9773	0.3512	24.144
Hs 840.T	CCLE	0.6859	7.3435	-1.3093	28.6571
Ca9-22	GDSC2	0.8586	4.9188	0.076	26.2407
PCI-15A	GDSC2	0.864	2.6423	0.6331	15.8714
JHU-011	GDSC2	0.9853	3.0869	0.601	15.533
CAL-27	GDSC2	1.01	4.7401	0.3078	24.5211
BICR 22	GDSC2	1.0128	2.336	0.9873	21.1768
PCI-04B	GDSC2	1.0229	3.1941	0.598	15.3938
KON	GDSC2	1.2264	5.6966	-0.3472	20.12
HO-1-N-1	GDSC2	1.3093	2.9687	1.2108	18.8188
HSC-3	GDSC2	1.4082	4.8903	0.6655	21.1854
CAL-33	GDSC2	1.4977	4.4097	0.9559	19.3458
JHU-029	GDSC2	1.9867	5.2055	0.5921	11.9469
KOSC-2	GDSC2	2.0999	3.9467	1.3178	7.0338
PE/CA-PJ15	GDSC2	2.2298	3.8425	1.4836	5.5816
JHU-022	GDSC2	2.3346	5.1783	1.4818	13.5168
HSC-4	GDSC2	2.4482	3.8363	2.1913	9.258
PCI-06A	GDSC2	2.7039	6.7387	0.4232	10.8904
HO-1-u-1	GDSC2	2.708	4.2281	2.2924	8.5543
SCC-15	GDSC2	2.73	6.8669	1.0348	14.7428
OSC-19	GDSC2	2.8589	6.8154	0.5055	9.9778
OSC-20	GDSC2	2.9073	5.2885	1.9749	8.9204
SCC-4	GDSC2	3.2105	6.1317	1.8231	8.9197
Detroit 562	GDSC2	3.2486	6.6455	1.5986	10.0992
PCI-30	GDSC2	3.3153	5.6115	2.1716	7.302
NCI-H3118	GDSC2	3.3251	9.2855	0.3427	16.7038
BICR 78	GDSC2	3.3472	6.3858	1.811	8.6229
DOK	GDSC2	3.3848	9.5319	0.2692	16.9098
BHY	GDSC2	3.843	11.0484	-0.8477	15.0788
SCC-25	GDSC2	3.9044	6.1416	1.5139	1.9591
BICR 10	GDSC2	4.0677	7.304	1.913	6.3315
UPCI-SCC-090	GDSC2	4.0688	6.8189	2.15	5.0062
BICR 31	GDSC2	4.2174	6.3064	1.6003	1.218
SKN-3	GDSC2	4.4892	11.9563	-0.0653	15.7544
LB771-HNC	GDSC2	4.9809	7.1439	2.5523	1.527
SCC-9	GDSC2	5.2928	10.299	1.3074	7.2303
SAT [Human HNSCC]	GDSC2	5.8122	10.2324	1.6551	4.649
BB49-HNC	GDSC2	6.5649	16.4923	-0.796	14.6337

Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JMSU-1	CCLE	-2.5444	-1.4136	-2.5445	47.6169
SCaBER	CCLE	-1.5552	1.4049	-1.6439	39.4483
T24	GDSC2; CCLE	-1.5371	0.5266	-1.552	39.0257
KMBC-2	CCLE	-0.2463	1.7949	-0.301	28.1174
647V	GDSC2	-0.1025	3.6267	-0.5027	32.9818
639V	GDSC2; CCLE	0.0934	1.2884	0.0906	26.993
BFTC-905	GDSC2	0.95	3.4389	0.7005	22.8264
KU-19-19	GDSC2	1.2006	5.3518	0.2537	24.0408
UM-UC-3	GDSC2; CCLE	1.5554	2.6989	1.5216	14.9068
CAL-29	GDSC2	1.8651	3.9941	1.5086	15.0601
5637	GDSC2; CCLE	3.0677	7.5137	1.0106	12.7655
RT-4	GDSC2; CCLE	3.1657	7.492	1.1053	12.0307
SW780	GDSC2; CCLE	3.9262	9.3049	0.8179	11.6909
J82	GDSC2	4.1445	6.3533	2.4247	3.3506
TCCSUP	GDSC2; CCLE	4.3064	8.06	1.7148	6.3596
HT-1376	GDSC2; CCLE	4.8775	6.8961	2.6043	1.2964
SW1710	GDSC2	5.1573	8.1511	2.211	2.8709
HT-1197	GDSC2; CCLE	5.1995	11.0068	0.9092	8.7128
RT-112	GDSC2; CCLE	5.7085	9.038	2.1224	2.3815

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JEG-3	GDSC2	-1.789	9.5391	-5.1009	46.0819
NT2-D1	GDSC2	-1.1062	3.1916	-1.4757	45.2534
TC-YIK	GDSC2	-0.8378	1.5497	-0.884	38.1302
SW954	GDSC2	0.3301	2.8069	-0.0012	21.7623
UWB1.289	GDSC2	0.7195	6.2855	-1.1143	25.9922
KGN	GDSC2	0.961	4.8484	0.2126	27.6019
NEC8	GDSC2	1.0886	3.3637	0.8731	21.3998
BPH-1	GDSC2	1.0921	3.6197	0.8011	21.7413
ME-180	GDSC2	1.1618	2.9669	1.0511	20.2222
HT-3	GDSC2	1.2783	2.8335	1.2035	18.9874
PA-1	GDSC2	1.2795	6.8423	-0.3356	26.4761
ACC-OV7	GDSC2	1.5066	5.0397	0.2355	15.734
Ca Ski	GDSC2	1.7463	3.6889	1.4899	15.6231
C-33 A	GDSC2	1.8644	5.4384	0.8936	18.3271
HEY	GDSC2	2.0641	5.1832	1.2105	15.9267
PWR-1E	GDSC2	2.1141	4.7226	1.4682	14.3531
CAL-39	GDSC2	2.1297	4.3916	1.6279	13.4363
OVCA433	GDSC2	2.2254	5.8255	0.4891	11.8485
JAR	GDSC2	2.2602	4.0827	1.3896	6.0846
DSH1	GDSC2	2.3281	4.192	1.919	11.1519
JHOS-3	GDSC2	2.5107	4.4461	1.4128	5.23
MS751	GDSC2	2.633	5.8319	1.455	12.7017
SKG-IIIa	GDSC2	2.7149	6.685	1.1111	14.3683
OMC-1 [Human cervical carcinoma]	GDSC2	2.762	5.0661	1.2971	5.3155
LB831-BLC	GDSC2	3.0457	6.9385	1.2785	12.4699
SW962	GDSC2	3.1832	7.7249	0.3003	10.3934
SiSo	GDSC2	3.2017	5.8007	1.981	8.0381
SW756	GDSC2	3.2159	6.7695	1.509	10.6975
DoTc2 4510	GDSC2	3.5049	8.2579	1.0048	12.7437
PEO1	GDSC2	3.6903	6.1646	2.1947	5.5751
C-4-I	GDSC2	3.8157	6.3703	2.1871	5.3346
SKN	GDSC2	3.8976	6.3132	2.2747	4.6639
SiHa	GDSC2	3.9235	5.5041	2.6822	2.3616
NCC-IT	GDSC2	4.1134	8.1586	1.5273	9.2051
OV17R	GDSC2	4.1625	7.233	1.1776	3.3256
HEC-1	GDSC2	4.6264	6.0812	2.8184	0.7882
OVCA420	GDSC2	4.8787	7.3566	2.4067	2.5382
HeLa	GDSC2	5.4292	11.7286	0.7185	9.9695
OVMIU	GDSC2	6.0052	8.2929	2.5614	0.6955

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Irinotecan

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Regorafenib	DMHSY1I	Moderate	Decreased metabolism of Irinotecan caused by Regorafenib mediated inhibition of UGT.	Colorectal cancer [2B91]	[25]

Coadministration of a Drug Treating the Disease Different from Irinotecan (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Irinotecan caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[26]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Irinotecan caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[27]
Arn-509	DMT81LZ	Major	Increased metabolism of Irinotecan caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[26]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[28]
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Irinotecan caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[25]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Irinotecan caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[25]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Irinotecan caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[29]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Irinotecan caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[25]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Irinotecan and Roflumilast.	Asthma [CA23]	[27]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Irinotecan caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[28]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Irinotecan caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
ABT-492	DMJFD2I	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[30]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Irinotecan caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[30]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Irinotecan caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[25]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[28]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Irinotecan caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[26]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Irinotecan caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Tucatinib	DMBESUA	Major	Decreased metabolism of Irinotecan caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Irinotecan caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
PF-04449913	DMSB068	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[27]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Irinotecan caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[26]
Atracurium	DM42HXN	Minor	Antagonize the effect of Irinotecan when combined with Atracurium.	Corneal disease [9A76-9A78]	[31]
Mivacurium	DM473VD	Minor	Antagonize the effect of Irinotecan when combined with Mivacurium.	Corneal disease [9A76-9A78]	[31]
Pancuronium	DMB0VY8	Minor	Antagonize the effect of Irinotecan when combined with Pancuronium.	Corneal disease [9A76-9A78]	[31]
Tubocurarine	DMBZIVP	Minor	Antagonize the effect of Irinotecan when combined with Tubocurarine.	Corneal disease [9A76-9A78]	[31]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Irinotecan caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[25]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Irinotecan caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[25]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Irinotecan caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[32]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Irinotecan caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[25]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Irinotecan caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[25]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Irinotecan caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[25]
Primidone	DM0WX6I	Major	Increased metabolism of Irinotecan caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Irinotecan caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Irinotecan caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Irinotecan caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Irinotecan caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Irinotecan caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Irinotecan caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Irinotecan caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Irinotecan caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Irinotecan caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[26]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Irinotecan caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[25]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Irinotecan caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[25]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Irinotecan caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[25]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Irinotecan caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[26]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Irinotecan caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[25]
Telaprevir	DMMRV29	Major	Decreased metabolism of Irinotecan caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[25]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Irinotecan caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[25]
Rifampin	DMA8J1G	Major	Increased metabolism of Irinotecan caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Rifapentine	DMCHV4I	Major	Increased metabolism of Irinotecan caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Irinotecan caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Irinotecan caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Saquinavir	DMG814N	Major	Decreased metabolism of Irinotecan caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Irinotecan caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Irinotecan caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Irinotecan caused by Atazanavir mediated inhibition of UGT.	Human immunodeficiency virus disease [1C60-1C62]	[25]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[34]
Gemfibrozil	DMD8Q3J	Major	Decreased metabolism of Irinotecan caused by Gemfibrozil mediated inhibition of UGT.	Hyper-lipoproteinaemia [5C80]	[28]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Irinotecan and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[35]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Irinotecan caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[25]
Conivaptan	DM1V329	Major	Decreased metabolism of Irinotecan caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[25]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Irinotecan caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[25]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Irinotecan caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Irinotecan and Denosumab.	Low bone mass disorder [FB83]	[36]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Irinotecan caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Ceritinib	DMB920Z	Major	Decreased metabolism of Irinotecan caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Irinotecan caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[26]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[37]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Irinotecan caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[25]
Idelalisib	DM602WT	Major	Decreased metabolism of Irinotecan caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[25]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Irinotecan caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[26]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Irinotecan caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[27]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[38]
Exjade	DMHPRWG	Moderate	Increased metabolism of Irinotecan caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[26]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Irinotecan and Thalidomide.	Multiple myeloma [2A83]	[39]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Irinotecan and Tecfidera.	Multiple sclerosis [8A40]	[40]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Irinotecan and Siponimod.	Multiple sclerosis [8A40]	[28]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Irinotecan and Fingolimod.	Multiple sclerosis [8A40]	[41]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Irinotecan and Ocrelizumab.	Multiple sclerosis [8A40]	[42]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Irinotecan and Ozanimod.	Multiple sclerosis [8A40]	[27]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Irinotecan caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Irinotecan caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[25]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Irinotecan and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[43]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[44]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Irinotecan caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[28]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Irinotecan caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[25]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Irinotecan caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[25]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Irinotecan caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[45]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Irinotecan caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[46]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Irinotecan caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[25]
ABIRATERONE	DM8V75C	Moderate	Decreased metabolism of Irinotecan caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[25]
Enzalutamide	DMGL19D	Major	Increased metabolism of Irinotecan caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[26]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[47]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Irinotecan caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[25]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Irinotecan and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[48]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[30]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Irinotecan and Canakinumab.	Rheumatoid arthritis [FA20]	[49]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Irinotecan and Rilonacept.	Rheumatoid arthritis [FA20]	[49]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Irinotecan and Golimumab.	Rheumatoid arthritis [FA20]	[50]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Irinotecan caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[26]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Irinotecan and Leflunomide.	Rheumatoid arthritis [FA20]	[35]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Irinotecan when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[51]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Irinotecan caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[25]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Irinotecan caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[27]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Irinotecan caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Armodafinil	DMGB035	Moderate	Increased metabolism of Irinotecan caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[26]
LEE011	DMMX75K	Moderate	Decreased metabolism of Irinotecan caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
Pitolisant	DM8RFNJ	Moderate	Accelerated clearance of Irinotecan due to the transporter induction by Pitolisant.	Somnolence [MG42]	[27]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[52]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Irinotecan due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[53]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Irinotecan caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[25]
Pipecuronium	DM5F84A	Minor	Antagonize the effect of Irinotecan when combined with Pipecuronium.	Tonus and reflex abnormality [MB47]	[31]
Doxacurium	DMKE7L9	Minor	Antagonize the effect of Irinotecan when combined with Doxacurium.	Tonus and reflex abnormality [MB47]	[31]
Vecuronium	DMP0UK2	Minor	Antagonize the effect of Irinotecan when combined with Vecuronium.	Tonus and reflex abnormality [MB47]	[31]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Irinotecan and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[48]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Irinotecan and Azathioprine.	Transplant rejection [NE84]	[28]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Irinotecan and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[48]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[30]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Irinotecan due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[30]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Irinotecan caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[26]
Amiodarone	DMUTEX3	Moderate	Decreased metabolism of Irinotecan caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[25]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Irinotecan and Ganciclovir.	Virus infection [1A24-1D9Z]	[28]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Irinotecan and Valganciclovir.	Virus infection [1A24-1D9Z]	[28]

References

• [1] Irinotecan FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6823).
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] A genome-wide association study for irinotecan-related severe toxicities in patients with advanced non-small-cell lung cancer. Pharmacogenomics J. 2013 Oct;13(5):417-22. doi: 10.1038/tpj.2012.24. Epub 2012 Jun 5.
• [7] Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. Cancer Sci. 2013 Aug;104(8):1074-82. doi: 10.1111/cas.12186. Epub 2013 Jun 10.
• [8] Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther Drug Monit. 2007 Oct;29(5):666-8. doi: 10.1097/FTD.0b013e3181357364.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets. 2008 Aug;8(5):414-20.
• [11] Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab Dispos. 2002 Jul;30(7):763-70.
• [12] P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett. 2010 Dec;4(4):195-201.
• [13] ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
• [14] Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol. 2006 Sep;58(3):374-83.
• [15] Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.
• [16] Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
• [17] Drugs that may have potential CYP2B6 interactions.
• [18] Drug Interactions Flockhart Table
• [19] Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
• [20] Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 1996 Aug 15;56(16):3752-7.
• [21] Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
• [22] In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther. 2005 Jun;4(6):885-900.
• [23] Gene expression profile of colon cancer cell lines treated with SN-38. Chemotherapy. 2010;56(1):17-25. doi: 10.1159/000287353. Epub 2010 Feb 24.
• [24] Gene expression analysis using human cancer xenografts to identify novel predictive marker genes for the efficacy of 5-fluorouracil-based drugs. Cancer Sci. 2006 Jun;97(6):510-22. doi: 10.1111/j.1349-7006.2006.00204.x.
• [25] Canadian Pharmacists Association.
• [26] Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
• [27] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [28] Cerner Multum, Inc. "Australian Product Information.".
• [29] Di YM, Li CG, Xue CC, Zhou SF "Clinical drugs that interact with St. John's wort and implication in drug development." Curr Pharm Des 14 (2008): 1723-42. [PMID: 18673195]
• [30] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [31] Product Information. Camptosar (irinotecan). Pharmacia and Upjohn, Kalamazoo, MI.
• [32] Kuhn JG "Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report." Oncology (Williston Park 16(8 Suppl 7) (2002): 33-40. [PMID: 12199631]
• [33] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [34] Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
• [35] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [36] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [37] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [38] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [39] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [40] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [41] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [42] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [43] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [44] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [45] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [46] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [47] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [48] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [49] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [50] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [51] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
• [52] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [53] Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]